Three-in-One Stop Computed Topography Angiography(CTA) and CT Perfusion(CTP) in Cerebrovascular Disease

NCT ID: NCT06890468

Last Updated: 2025-03-24

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Total Enrollment: 1000 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2025-03-16
• Study Completion Date: 2029-12-30

Brief Summary

This research takes patients with cerebrovascular diseases as the research subjects and employs the experimental design of a prospective cohort study, aiming to innovatively develop and validate a "one-stop" multimodal CT examination scheme. The 301-CTAP multimodal CT technique implies that three modalities are acquired through a single collection, including head and neck CTA (head and neck CTA), multiphase CTA imaging of the brain (multiphase CTA), and CT perfusion imaging of the brain (CT perfusion).

Detailed Description

In the diagnosis of cerebrovascular diseases, CT examination, with its advantages of high resolution, non-invasiveness, and rapid imaging, has long become an indispensable diagnostic tool. Especially in the "Chinese Guidelines for the Standardized Application of Cerebrovascular Disease Imaging", the "one-stop" CT examination mode - including CT plain scan (NCCT), CT angiography (CTA), and CT perfusion imaging (CTP) - has been strongly recommended as the preferred imaging examination method for suspected acute large artery occlusion ischemic cerebrovascular diseases. However, traditional multimodal CT examinations require large amounts of contrast agents, multiple scans for blood flow and vascular imaging, multiple injections of contrast agents, high radiation doses, and low image signal-to-noise ratios. How to simultaneously evaluate cerebral blood flow perfusion and cerebral vessels through a single examination is a major clinical need that urgently needs to be addressed.

This study takes patients with cerebrovascular diseases as the research subjects and adopts a prospective cohort study design. The aim is to innovatively develop and verify a "one-stop" multimodal CT examination scheme. The 301-CTAP multimodal CT technology means that the three modalities are obtained through a single acquisition, including head and neck CTA (CTA), multiphase CTA (CTA) imaging of the brain, and CT perfusion imaging of the brain. The 301-CTAP multimodal CT technology can reduce the duration of CT examination for patients with cerebrovascular diseases without reducing the imaging content, and reduce the amount of contrast agents, X-ray radiation dose, and the incidence of contrast agent allergy and related adverse events. It provides innovative and important technical support for the diagnosis and assessment of acute stroke and other cerebrovascular emergencies; the acquisition of multiple key imaging indicators features enables individualized comprehensive imaging assessment, prediction of clinical functional prognosis and stroke recurrence risk for patients; the implementation of this project helps optimize the imaging examination path in the diagnosis and treatment of cerebrovascular diseases.

Conditions

Radiology; Vascular Diseases

Study Design

• Observational Model Type: CASE_ONLY
• Study Time Perspective: PROSPECTIVE

Eligibility Criteria

Inclusion Criteria

• Age≥18 <100years
• Head and neck artery stenosis/occlusion, moyamoya disease, aneurysm, artery dissection, etc., may include patients with acute stroke, chronic cerebral ischemia, and asymptomatic patients. After clinical assessment, CT perfusion imaging is required
• The image quality meets the requirements of diagnosis and post-processing
• Patients who follow the scanning strategy to complete the examination
• The patient or his or her family agrees to provide clinical data and follow-up
• Patients or their families sign informed consent forms

Exclusion Criteria

• < 18 years old
• People who are allergic to iodine contrast agents, or who cannot be tested temporarily due to taking metformin or aminoglycoside drugs
• Renal failure patient
• Severe cardiac insufficiency
• Severe liver damage
• Patients with an expected survival of less than 1 year
• Patients with cerebrovascular diseasePregnant woman

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 100 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Xin Lou

OTHER

Sponsor Role: lead

Responsible Party

Xin Lou

Chairman

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Xin Lou

Role: STUDY_CHAIR

Chinese PLA General Hospital

Locations

Chinese PLA General Hospital, Beijing, Beijing 100853

Beijing, , China

Countries

China

Central Contacts

xiaoxuan Ma

Role: CONTACT

xiaoxuan5686@126.com

+8613681126807

Other Identifiers

301-CTAP

Identifier Type: -

Identifier Source: org_study_id